Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939224 | 0.88 | EPHX2 (0.42) | S1PR1EPHX1EPHX2CA12CA1 | |
| SCHEMBL979925 | 0.85 | EPHX2 (0.47) | S1PR1EPHX1EPHX2CA12CA1 | |
| SCHEMBL978582 | 0.85 | S1PR1 (0.45) | S1PR1EPHX1EPHX2CA12CA1 | |
| SCHEMBL979229 | 0.84 | S1PR1 (0.47) | S1PR1EPHX1EPHX2CA12CA1 | |
| SCHEMBL979549 | 0.84 | S1PR1 (0.39) | S1PR1EPHX1EPHX2CA12CA1 | |
| Iodide SCHEMBL979814 | 0.83 | S1PR1 (0.46) | S1PR1EPHX1EPHX2CA12CA1 | |
| Iodide SCHEMBL980182 | 0.83 | EPHX2 (0.46) | S1PR1EPHX1EPHX2CA12CA1 | |
| Iodide SCHEMBL978539 | 0.82 | EPHX2 (0.43) | S1PR1EPHX1EPHX2CA12CA1 | |
| SCHEMBL980299 | 0.82 | EPHX2 (0.44) | S1PR1EPHX1EPHX2CA12CA1 | |
| SCHEMBL979271 | 0.79 | AKT1 (0.47) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680282-B2 | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-03-25 | — | — | US | disclosed |
| US-20110015174-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015174-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | S1PR1 261/4885EPHX1 3878/4885EPHX2 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.